Glucagon-like peptide-1 gene therapy - Sanofi
Alternative Names: Type 2 diabetes gene therapyLatest Information Update: 31 Mar 2022
At a glance
- Originator Genzyme Corporation
- Developer Sanofi
- Class Glucagon-like peptides
- Mechanism of Action Glucagon-like peptide 1 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 27 Dec 2016 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
- 04 May 2006 No development reported - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
- 26 Jun 2003 Data presented at the 63rd Scientific Sessions of the American Diabetes Association (ADA-2003)have been added to the Diabetes pharmacodynamics section